Novo Nordisk A/S : The underlying trend is to the upside
Entry price | Target | Stop-loss | Potential |
---|
DKK 335.05 |
DKK 350 |
DKK 327.5 |
+4.46% |
---|
The underlying tendency is to the upside for shares in Novo Nordisk AS and the timing is opportune to get back into the stock. A comeback of the upward dynamic can be anticipated.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths● The group's activity appears highly profitable thanks to its outperforming net margins.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● Considering the small differences between the analysts' various estimates, the group's business visibility is good.
● Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
● The stock is in a well-established, long-term rising trend above the technical support level at 310 DKK
Weaknesses● The stock is close to a major daily resistance at DKK 348.4, which should be gotten rid of so as to gain new appreciation potential.
● The company's earnings releases usually do not meet expectations.
● Based on current prices, the company has particularly high valuation levels.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
Surperformance is Buy on NOVO NORDISK A/S since 2023-09-13
.